Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers
Despite modest survival benefits, current immunotherapy pricing severely limits global accessibility. Policy reform and pricing strategies are needed to ensure equitable cancer care.
Authors
- Rathan Raghunath Shetty
- Labani Kole (ORCID: https://orcid.org/0000-0002-2940-8507)
- Satish Nair (ORCID: https://orcid.org/0000-0001-7689-5355)
- Poonam Joshi
- Kumar Prabhash
- Richard Sullivan
- Arjun Gurmeet Singh
- Sarbani Ghosh Laskar
- Pankaj Chaturvedi
Institutions
- Tata Memorial Hospital (IN)
- London Cancer (GB)
Publication Details
- Journal
- Head & Neck
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1002/hed.70212
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00